{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,11]],"date-time":"2026-10-11T03:00:08Z","timestamp":1791687608632,"version":"4.3.4"},"reference-count":75,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2018,7,26]],"date-time":"2018-07-26T00:00:00Z","timestamp":1532563200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs Aging"],"published-print":{"date-parts":[[2018,9]]},"DOI":"10.1007\/s40266-018-0576-9","type":"journal-article","created":{"date-parts":[[2018,7,26]],"date-time":"2018-07-26T00:44:55Z","timestamp":1532565895000},"page":"781-789","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":35,"title":["Invasive Candidiasis in the Elderly: Considerations for Drug Therapy"],"prefix":"10.1007","volume":"35","author":[{"given":"B. G. J.","family":"Dekkers","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Veringa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D. J. E.","family":"Marriott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. M.","family":"Boonstra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K. C. M.","family":"van der Elst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F. F.","family":"Doukas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. J.","family":"McLachlan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan-Willem C.","family":"Alffenaar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,7,26]]},"reference":[{"key":"576_CR1","doi-asserted-by":"publisher","first-page":"e0176576","DOI":"10.1371\/journal.pone.0176576","volume":"12","author":"F Barchiesi","year":"2017","unstructured":"Barchiesi F, Orsetti E, Mazzanti S, Trave F, Salvi A, Nitti C, et al. Candidemia in the elderly: what does it change? PLoS One. 2017;12:e0176576.","journal-title":"PLoS One"},{"key":"576_CR2","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1093\/cid\/civ1194","volume":"62","author":"PG Pappas","year":"2016","unstructured":"Pappas PG, Kauffman CA, Andes DR, Clancy CJ, Marr KA, Ostrosky-Zeichner L, et al. Executive summary: clinical practice guideline for the management of candidiasis: 2016 update by the Infectious Diseases Society of America. Clin Infect Dis. 2016;62:409\u201317.","journal-title":"Clin Infect Dis."},{"issue":"Suppl 7","key":"576_CR3","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1111\/1469-0691.12039","volume":"18","author":"OA Cornely","year":"2012","unstructured":"Cornely OA, Bassetti M, Calandra T, Garbino J, Kullberg BJ, Lortholary O, et al. ESCMID guideline for the diagnosis and management of Candida diseases 2012: non-neutropenic adult patients. Clin Microbiol Infect. 2012;18(Suppl 7):19\u201337.","journal-title":"Clin Microbiol Infect."},{"key":"576_CR4","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1111\/myc.12677","volume":"60","author":"A Ramos-Mart\u00ednez","year":"2017","unstructured":"Ramos-Mart\u00ednez A, Vicente-L\u00f3pez N, S\u00e1nchez-Romero I, Padilla B, Merino-Amador P, Garnacho-Montero J, et al. Epidemiology and prognosis of candidaemia in elderly patients. Mycoses. 2017;60:808\u201317.","journal-title":"Mycoses."},{"key":"576_CR5","first-page":"207","volume":"30","author":"A Lerma","year":"2017","unstructured":"Lerma A, Cantero E, Soriano M, Orden B, Mu\u00f1ez E, Ramos-Martinez A. Clinical presentation of candidaemia in elderly patients: experience in a single institution. Rev Esp Quimioter. 2017;30:207\u201312.","journal-title":"Rev Esp Quimioter."},{"key":"576_CR6","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1186\/s12879-014-0609-x","volume":"14","author":"H Wang","year":"2014","unstructured":"Wang H, Liu N, Yin M, Han H, Yue J, Zhang F, et al. The epidemiology, antifungal use and risk factors of death in elderly patients with candidemia: a multicentre retrospective study. BMC Infect Dis. 2014;14:609.","journal-title":"BMC Infect Dis."},{"key":"576_CR7","doi-asserted-by":"publisher","first-page":"e442","DOI":"10.1016\/j.ijid.2012.02.005","volume":"16","author":"T Guimar\u00e3es","year":"2012","unstructured":"Guimar\u00e3es T, Nucci M, Mendon\u00e7a JS, Martinez R, Brito LR, Silva N, et al. Epidemiology and predictors of a poor outcome in elderly patients with candidemia. Int J Infect Dis. 2012;16:e442\u20137.","journal-title":"Int J Infect Dis."},{"key":"576_CR8","doi-asserted-by":"publisher","first-page":"892","DOI":"10.1093\/cid\/ciu959","volume":"60","author":"E Mylonakis","year":"2015","unstructured":"Mylonakis E, Clancy CJ, Ostrosky-Zeichner L, Garey KW, Alangaden GJ, Vazquez JA, et al. T2 magnetic resonance assay for the rapid diagnosis of candidemia in whole blood: a clinical trial. Clin Infect Dis. 2015;60:892\u20139.","journal-title":"Clin Infect Dis."},{"key":"576_CR9","doi-asserted-by":"publisher","first-page":"750","DOI":"10.1093\/cid\/ciq206","volume":"52","author":"DE Karageorgopoulos","year":"2011","unstructured":"Karageorgopoulos DE, Vouloumanou EK, Ntziora F, Michalopoulos A, Rafailidis PI, Falagas ME. \u03b2-D-glucan assay for the diagnosis of invasive fungal infections: a meta-analysis. Clin Infect Dis. 2011;52:750\u201370.","journal-title":"Clin Infect Dis."},{"key":"576_CR10","doi-asserted-by":"publisher","first-page":"1240","DOI":"10.1093\/cid\/cis200","volume":"54","author":"MH Nguyen","year":"2012","unstructured":"Nguyen MH, Wissel MC, Shields RK, Salomoni MA, Hao B, Press EG, et al. Performance of Candida real-time polymerase chain reaction, \u03b2-d-glucan assay, and blood cultures in the diagnosis of invasive candidiasis. Clin Infect Dis. 2012;54:1240\u20138.","journal-title":"Clin Infect Dis."},{"key":"576_CR11","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1038\/clpt.2009.1","volume":"85","author":"AJ McLachlan","year":"2009","unstructured":"McLachlan AJ, Hilmer SN, Le Couteur DG. Variability in response to medicines in older people: phenotypic and genotypic factors. Clin Pharmacol Ther. 2009;85:431\u20133.","journal-title":"Clin Pharmacol Ther."},{"key":"576_CR12","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1093\/gerona\/glr118","volume":"67","author":"AJ McLachlan","year":"2012","unstructured":"McLachlan AJ, Pont LG. Drug metabolism in older people\u2014a key consideration in achieving optimal outcomes with medicines. J Gerontol A Biol Sci Med Sci. 2012;67:175\u201380.","journal-title":"J Gerontol A Biol Sci Med Sci."},{"key":"576_CR13","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1111\/j.1472-8206.2007.00473.x","volume":"21","author":"SN Hilmer","year":"2007","unstructured":"Hilmer SN, McLachlan AJ, Le Couteur DG. Clinical pharmacology in the geriatric patient. Fundam Clin Pharmacol. 2007;21:217\u201330.","journal-title":"Fundam Clin Pharmacol."},{"key":"576_CR14","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1124\/pr.56.2.4","volume":"56","author":"AJ McLean","year":"2004","unstructured":"McLean AJ, Le Couteur DG. Aging biology and geriatric clinical pharmacology. Pharmacol Rev. 2004;56:163\u201384.","journal-title":"Pharmacol Rev."},{"key":"576_CR15","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1038\/clpt.2008.224","volume":"85","author":"S Hilmer","year":"2009","unstructured":"Hilmer S, Gnjidic D. The effects of polypharmacy in older adults. Clin Pharmacol Ther. 2009;85:86\u20138.","journal-title":"Clin Pharmacol Ther."},{"key":"576_CR16","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1016\/j.jclinepi.2012.02.018","volume":"65","author":"D Gnjidic","year":"2012","unstructured":"Gnjidic D, Hilmer SN, Blyth FM, Naganathan V, Waite L, Seibel MJ, et al. Polypharmacy cutoff and outcomes: five or more medicines were used to identify community-dwelling older men at risk of different adverse outcomes. J Clin Epidemiol. 2012;65:989\u201395.","journal-title":"J Clin Epidemiol."},{"key":"576_CR17","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1007\/s00228-012-1387-2","volume":"69","author":"RE Hubbard","year":"2013","unstructured":"Hubbard RE, O\u2019Mahony MS, Woodhouse KW. Medication prescribing in frail older people. Eur J Clin Pharmacol. 2013;69:319\u201326.","journal-title":"Eur J Clin Pharmacol."},{"key":"576_CR18","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1007\/s00228-014-1652-7","volume":"70","author":"C Johnston","year":"2014","unstructured":"Johnston C, Hilmer SN, McLachlan AJ, Matthews ST, Carroll PR, Kirkpatrick CM. The impact of frailty on pharmacokinetics in older people: using gentamicin population pharmacokinetic modeling to investigate changes in renal drug clearance by glomerular filtration. Eur J Clin Pharmacol. 2014;70:549\u201355.","journal-title":"Eur J Clin Pharmacol."},{"key":"576_CR19","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1016\/S1473-3099(14)70036-2","volume":"14","author":"JA Roberts","year":"2014","unstructured":"Roberts JA, Abdul-Aziz MH, Lipman J, Mouton JW, Vinks AA, Felton TW, et al. Individualised antibiotic dosing for patients who are critically ill: challenges and potential solutions. Lancet Infect Dis. 2014;14:498\u2013509.","journal-title":"Lancet Infect Dis."},{"key":"576_CR20","doi-asserted-by":"publisher","first-page":"297","DOI":"10.2165\/00003088-200847050-00002","volume":"47","author":"JM Butler","year":"2008","unstructured":"Butler JM, Begg EJ. Free drug metabolic clearance in elderly people. Clin Pharmacokinet. 2008;47:297\u2013321.","journal-title":"Clin Pharmacokinet."},{"key":"576_CR21","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1111\/j.1365-2567.2007.02555.x","volume":"120","author":"D Aw","year":"2007","unstructured":"Aw D, Silva AB, Palmer DB. Immunosenescence: emerging challenges for an ageing population. Immunology. 2007;120:435\u201346.","journal-title":"Immunology."},{"key":"576_CR22","doi-asserted-by":"publisher","first-page":"i12","DOI":"10.1093\/jac\/dkx029","volume":"72","author":"KE Stott","year":"2017","unstructured":"Stott KE, Hope WW. Therapeutic drug monitoring for invasive mould infections and disease: pharmacokinetic and pharmacodynamic considerations. J Antimicrob Chemother. 2017;72:i12\u20138.","journal-title":"J Antimicrob Chemother."},{"key":"576_CR23","doi-asserted-by":"publisher","first-page":"S28","DOI":"10.1086\/504492","volume":"43","author":"ESD Ashley","year":"2006","unstructured":"Ashley ESD, Lewis R, Lewis JS, Martin C, Andes D. Pharmacology of systemic antifungal agents. Clin Infect Dis. 2006;43:S28\u201339.","journal-title":"Clin Infect Dis."},{"key":"576_CR24","doi-asserted-by":"publisher","first-page":"i26","DOI":"10.1093\/jac\/dkx446","volume":"73","author":"A Mourad","year":"2018","unstructured":"Mourad A, Perfect JR. Tolerability profile of the current antifungal armoury. J Antimicrob Chemother. 2018;73:i26\u201332.","journal-title":"J Antimicrob Chemother."},{"key":"576_CR25","doi-asserted-by":"publisher","first-page":"1647","DOI":"10.1345\/aph.1M237","volume":"43","author":"AJ Sucher","year":"2009","unstructured":"Sucher AJ, Chahine EB, Balcer HE. Echinocandins: the newest class of antifungals. Ann Pharmacother. 2009;43:1647\u201357.","journal-title":"Ann Pharmacother."},{"key":"576_CR26","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1016\/j.diagmicrobio.2016.02.009","volume":"85","author":"M Castanheira","year":"2016","unstructured":"Castanheira M, Messer SA, Rhomberg PR, Pfaller MA. Antifungal susceptibility patterns of a global collection of fungal isolates: results of the SENTRY Antifungal Surveillance Program (2013). Diagn Microbiol Infect Dis. 2016;85:200\u20134.","journal-title":"Diagn Microbiol Infect Dis."},{"key":"576_CR27","doi-asserted-by":"publisher","first-page":"2409","DOI":"10.1128\/AAC.01657-09","volume":"54","author":"J-L Wang","year":"2010","unstructured":"Wang J-L, Chang C-H, Young-Xu Y, Chan KA. Systematic review and meta-analysis of the tolerability and hepatotoxicity of antifungals in empirical and definitive therapy for invasive fungal infection. Antimicrob Agents Chemother. 2010;54:2409\u201319.","journal-title":"Antimicrob Agents Chemother."},{"key":"576_CR28","doi-asserted-by":"publisher","first-page":"11","DOI":"10.2165\/11585270-000000000-00000","volume":"71","author":"SC-A Chen","year":"2011","unstructured":"Chen SC-A, Slavin MA, Sorrell TC. Echinocandin antifungal drugs in fungal infections: a comparison. Drugs. 2011;71:11\u201341.","journal-title":"Drugs."},{"key":"576_CR29","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1007\/s10096-008-0486-6","volume":"27","author":"MJ DiNubile","year":"2008","unstructured":"DiNubile MJ, Strohmaier KM, Lupinacci RJ, Meibohm AR, Sable CA, Kartsonis NA. Efficacy and safety of caspofungin therapy in elderly patients with proven or suspected invasive fungal infections. Eur J Clin Microbiol Infect Dis. 2008;27:663\u201370.","journal-title":"Eur J Clin Microbiol Infect Dis."},{"key":"576_CR30","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1016\/j.ijantimicag.2012.07.018","volume":"40","author":"G Dimopoulos","year":"2012","unstructured":"Dimopoulos G, Paiva J-A, Meersseman W, Pachl J, Grigoras I, Sganga G, et al. Efficacy and safety of anidulafungin in elderly, critically ill patients with invasive Candida infections: a post hoc analysis. Int J Antimicrob Agents. 2012;40:521\u20136.","journal-title":"Int J Antimicrob Agents."},{"key":"576_CR31","doi-asserted-by":"publisher","first-page":"e0180050","DOI":"10.1371\/journal.pone.0180050","volume":"12","author":"C-H Lee","year":"2017","unstructured":"Lee C-H, Lin J-C, Ho C-L, Sun M, Yen W-T, Lin C. Efficacy and safety of micafungin versus extensive azoles in the prevention and treatment of invasive fungal infections for neutropenia patients with hematological malignancies: a meta-analysis of randomized controlled trials. PLoS One. 2017;12:e0180050.","journal-title":"PLoS One."},{"key":"576_CR32","doi-asserted-by":"publisher","first-page":"e02154-17","DOI":"10.1128\/AAC.02154-17","volume":"62","author":"AJ Lepak","year":"2018","unstructured":"Lepak AJ, Zhao M, VanScoy B, Ambrose PG, Andes DR. Pharmacodynamics of a long-acting echinocandin, CD101, in a neutropenic invasive-candidiasis murine model using an extended-interval dosing design. Antimicrob Agents Chemother. 2018;62:e02154-17.","journal-title":"Antimicrob Agents Chemother."},{"key":"576_CR33","doi-asserted-by":"publisher","first-page":"1298","DOI":"10.1128\/JCM.40.4.1298-1302.2002","volume":"40","author":"DJ Diekema","year":"2002","unstructured":"Diekema DJ, Messer SA, Brueggemann AB, Coffman SL, Doern GV, Herwaldt LA, et al. Epidemiology of candidemia: 3-year results from the emerging infections and the epidemiology of Iowa organisms study. J Clin Microbiol. 2002;40:1298\u2013302.","journal-title":"J Clin Microbiol."},{"key":"576_CR34","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1016\/j.archger.2016.04.001","volume":"65","author":"B Benito-Cruz","year":"2016","unstructured":"Benito-Cruz B, Aranda-Romo S, L\u00f3pez-Esqueda FJ, de la Rosa-Garc\u00eda E, Rosas-Hern\u00e1ndez R, S\u00e1nchez-Vargas LO. Oral Candida isolates and fluconazole susceptibility patterns in older Mexican women. Arch Gerontol Geriatr. 2016;65:204\u201310.","journal-title":"Arch Gerontol Geriatr."},{"key":"576_CR35","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1007\/s40520-014-0251-x","volume":"27","author":"R Luzzati","year":"2015","unstructured":"Luzzati R, Cavinato S, Deiana ML, Rosin C, Maurel C, Borelli M. Epidemiology and outcome of nosocomial candidemia in elderly patients admitted prevalently in medical wards. Aging Clin Exp Res. 2015;27:131\u20137.","journal-title":"Aging Clin Exp Res."},{"key":"576_CR36","doi-asserted-by":"publisher","first-page":"1441","DOI":"10.1086\/598327","volume":"48","author":"RJM Br\u00fcggemann","year":"2009","unstructured":"Br\u00fcggemann RJM, Alffenaar J-WC, Blijlevens NMA, Billaud EM, Kosterink JGW, Verweij PE, et al. Clinical relevance of the pharmacokinetic interactions of azole antifungal drugs with other coadministered agents. Clin Infect Dis. 2009;48:1441\u201358.","journal-title":"Clin Infect Dis."},{"key":"576_CR37","volume-title":"Summary of product characteristics: Vfend","author":"Pfizer","year":"2008","unstructured":"Pfizer. Summary of product characteristics: Vfend. New York: Pfizer; 2008."},{"key":"576_CR38","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1093\/cid\/cis599","volume":"55","author":"WB Park","year":"2012","unstructured":"Park WB, Kim N-H, Kim K-H, Lee SH, Nam W-S, Yoon SH, et al. The effect of therapeutic drug monitoring on safety and efficacy of voriconazole in invasive fungal infections: a randomized controlled trial. Clin Infect Dis. 2012;55:1080\u20137.","journal-title":"Clin Infect Dis."},{"key":"576_CR39","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1086\/524669","volume":"46","author":"A Pascual","year":"2008","unstructured":"Pascual A, Calandra T, Bolay S, Buclin T, Bille J, Marchetti O. Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes. Clin Infect Dis. 2008;46:201\u201311.","journal-title":"Clin Infect Dis."},{"key":"576_CR40","doi-asserted-by":"publisher","first-page":"4793","DOI":"10.1128\/AAC.00626-12","volume":"56","author":"MJ Dolton","year":"2012","unstructured":"Dolton MJ, Ray JE, Chen SC-A, Ng K, Pont LG, McLachlan AJ. Multicenter study of voriconazole pharmacokinetics and therapeutic drug monitoring. Antimicrob Agents Chemother. 2012;56:4793\u20139.","journal-title":"Antimicrob Agents Chemother."},{"key":"576_CR41","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1093\/jac\/dkw349","volume":"72","author":"A Veringa","year":"2017","unstructured":"Veringa A, ter Avest M, Span LFR, van den Heuvel ER, Touw DJ, Zijlstra JG, et al. Voriconazole metabolism is influenced by severe inflammation: a prospective study. J Antimicrob Chemother. 2017;72:261\u20137.","journal-title":"J Antimicrob Chemother."},{"key":"576_CR42","doi-asserted-by":"publisher","first-page":"1321","DOI":"10.1016\/S0149-2918(03)80126-1","volume":"25","author":"L Jeu","year":"2003","unstructured":"Jeu L, Piacenti FJ, Lyakhovetskiy AG, Fung HB. Voriconazole. Clin Ther. 2003;25:1321\u201381.","journal-title":"Clin Ther."},{"key":"576_CR43","doi-asserted-by":"publisher","first-page":"649","DOI":"10.2165\/00003088-200645070-00002","volume":"45","author":"U Theuretzbacher","year":"2006","unstructured":"Theuretzbacher U, Ihle F, Derendorf H. Pharmacokinetic\/pharmacodynamic profile of voriconazole. Clin Pharmacokinet. 2006;45:649\u201363.","journal-title":"Clin Pharmacokinet."},{"key":"576_CR44","volume-title":"Summary of product characteristics: Diflucan","author":"Pfizer","year":"2008","unstructured":"Pfizer. Summary of product characteristics: Diflucan. Kent: Pfizer; 2008."},{"key":"576_CR45","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1086\/444500","volume":"41","author":"RL Trotman","year":"2005","unstructured":"Trotman RL, Williamson JC, Shoemaker DM, Salzer WL. Antibiotic dosing in critically ill adult patients receiving continuous renal replacement therapy. Clin Infect Dis. 2005;41:1159\u201366.","journal-title":"Clin Infect Dis."},{"key":"576_CR46","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1128\/AAC.00705-08","volume":"53","author":"D Andes","year":"2009","unstructured":"Andes D, Pascual A, Marchetti O. Antifungal therapeutic drug monitoring: established and emerging indications. Antimicrob Agents Chemother. 2009;53:24\u201334.","journal-title":"Antimicrob Agents Chemother."},{"key":"576_CR47","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1517\/14740338.2013.827168","volume":"12","author":"AS Loo","year":"2013","unstructured":"Loo AS, Muhsin SA, Walsh TJ. Toxicokinetic and mechanistic basis for the safety and tolerability of liposomal amphotericin B. Expert Opin Drug Saf. 2013;12:881\u201395.","journal-title":"Expert Opin Drug Saf."},{"key":"576_CR48","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1128\/AAC.00265-11","volume":"56","author":"G W\u00fcrthwein","year":"2012","unstructured":"W\u00fcrthwein G, Young C, Lanvers-Kaminsky C, Hempel G, Trame MN, Schwerdtfeger R, et al. Population pharmacokinetics of liposomal amphotericin B and caspofungin in allogeneic hematopoietic stem cell recipients. Antimicrob Agents Chemother. 2012;56:536\u201343.","journal-title":"Antimicrob Agents Chemother."},{"key":"576_CR49","doi-asserted-by":"publisher","first-page":"37","DOI":"10.2174\/157488407779422311","volume":"2","author":"R Bellmann","year":"2007","unstructured":"Bellmann R. Clinical pharmacokinetics of systemically administered antimycotics. Curr Clin Pharmacol. 2007;2:37\u201358.","journal-title":"Curr Clin Pharmacol."},{"key":"576_CR50","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1086\/322685","volume":"33","author":"CA Kauffman","year":"2001","unstructured":"Kauffman CA. Fungal infections in older adults. Clin Infect Dis. 2001;33:550\u20135.","journal-title":"Clin Infect Dis."},{"key":"576_CR51","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1086\/514672","volume":"27","author":"MH White","year":"1998","unstructured":"White MH, Bowden RA, Sandler ES, Graham ML, Noskin GA, Wingard JR, et al. Randomized, double-blind clinical trial of amphotericin B colloidal dispersion vs. amphotericin B in the empirical treatment of fever and neutropenia. Clin Infect Dis. 1998;27:296\u2013302.","journal-title":"Clin Infect Dis."},{"key":"576_CR52","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1056\/NEJM199903113401004","volume":"340","author":"TJ Walsh","year":"1999","unstructured":"Walsh TJ, Finberg RW, Arndt C, Hiemenz J, Schwartz C, Bodensteiner D, et al. Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. N Engl J Med. 1999;340:764\u201371.","journal-title":"N Engl J Med."},{"key":"576_CR53","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1093\/clinids\/22.2.315","volume":"22","author":"PK Sharkey","year":"1996","unstructured":"Sharkey PK, Graybill JR, Johnson ES, Hausrath SG, Pollard RB, Kolokathis A, et al. Amphotericin B lipid complex compared with amphotericin B in the treatment of cryptococcal meningitis in patients with AIDS. Clin Infect Dis. 1996;22:315\u201321.","journal-title":"Clin Infect Dis."},{"key":"576_CR54","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1016\/j.jinf.2004.07.004","volume":"50","author":"R Hooshmand-Rad","year":"2005","unstructured":"Hooshmand-Rad R, Chu A, Gotz V, Morris J, Batty S, Freifeld A. Use of amphotericin B lipid complex in elderly patients. J Infect. 2005;50:277\u201387.","journal-title":"J Infect."},{"key":"576_CR55","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1016\/j.jiac.2016.01.009","volume":"22","author":"S Ueda","year":"2016","unstructured":"Ueda S, Miyamoto S, Kaida K, Chizuka A, Kojima R, Takano J, et al. Safety and efficacy of treatment with liposomal amphotericin B in elderly patients at least 65\u00a0years old with hematological diseases. J Infect Chemother. 2016;22:287\u201391.","journal-title":"J Infect Chemother."},{"key":"576_CR56","doi-asserted-by":"publisher","first-page":"1162","DOI":"10.1093\/jac\/dkt508","volume":"69","author":"HR Ashbee","year":"2013","unstructured":"Ashbee HR, Barnes RA, Johnson EM, Richardson MD, Gorton R, Hope WW. Therapeutic drug monitoring (TDM) of antifungal agents: guidelines from the British Society for Medical Mycology. J Antimicrob Chemother. 2013;69:1162\u201376.","journal-title":"J Antimicrob Chemother."},{"key":"576_CR57","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.trac.2015.11.026","volume":"84","author":"A Veringa","year":"2016","unstructured":"Veringa A, Sturkenboom MGG, Dekkers BGJ, Koster RA, Roberts JA, Peloquin CA, et al. LC-MS\/MS for therapeutic drug monitoring of anti-infective drugs. Trends Anal Chem. 2016;84:34\u201340.","journal-title":"Trends Anal Chem."},{"key":"576_CR58","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1007\/s12281-015-0224-3","volume":"9","author":"RJM Br\u00fcggemann","year":"2015","unstructured":"Br\u00fcggemann RJM, Aarnoutse RE. Fundament and prerequisites for the application of an antifungal TDM service. Curr Fungal Infect Rep. 2015;9:122\u20139.","journal-title":"Curr Fungal Infect Rep."},{"key":"576_CR59","unstructured":"Lewis R, Bruggemann RJ, Padoin C, Maertens J, Marchetti O, Groll AH, et al. ECIL 6: triazole antifungal therapeutic drug monitoring. 2015. https:\/\/www.ebmt.org\/Contents\/Resources\/Library\/ECIL\/Pages\/ECIL.aspx . Accessed 1 Mar 2018."},{"key":"576_CR60","doi-asserted-by":"publisher","first-page":"2361","DOI":"10.1517\/14656566.2013.838217","volume":"14","author":"RH Drew","year":"2013","unstructured":"Drew RH, Townsend ML, Pound MW, Johnson SW, Perfect JR. Recent advances in the treatment of life-threatening, invasive fungal infections. Expert Opin Pharmacother. 2013;14:2361\u201374.","journal-title":"Expert Opin Pharmacother."},{"key":"576_CR61","doi-asserted-by":"publisher","first-page":"4782","DOI":"10.1128\/AAC.01083-10","volume":"55","author":"PF Troke","year":"2011","unstructured":"Troke PF, Hockey HP, Hope WW. Observational study of the clinical efficacy of voriconazole and its relationship to plasma concentrations in patients. Antimicrob Agents Chemother. 2011;55:4782\u20138.","journal-title":"Antimicrob Agents Chemother."},{"key":"576_CR62","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1007\/s12281-016-0255-4","volume":"10","author":"BGJ Dekkers","year":"2016","unstructured":"Dekkers BGJ, Bakker M, van der Elst KCM, Sturkenboom MGG, Veringa A, Span LFR, et al. Therapeutic drug monitoring of posaconazole: an update. Curr Fungal Infect Rep. 2016;10:51\u201361.","journal-title":"Curr Fungal Infect Rep."},{"key":"576_CR63","doi-asserted-by":"publisher","first-page":"e01582-16","DOI":"10.1128\/AAC.01582-16","volume":"61","author":"KCM Elst van der","year":"2016","unstructured":"van der Elst KCM, Veringa A, Zijlstra JG, Beishuizen A, Klont R, Brummelhuis-Visser P, et al. Low caspofungin exposure in patients in the intensive care unit. Antimicrob Agents Chemother. 2016;61:e01582-16.","journal-title":"Antimicrob Agents Chemother."},{"key":"576_CR64","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1128\/AAC.01607-13","volume":"58","author":"MJP Wanrooy van","year":"2014","unstructured":"van Wanrooy MJP, Rodgers MGG, Uges DRA, Arends JP, Zijlstra JG, van der Werf TS, et al. Low but sufficient anidulafungin exposure in critically ill patients. Antimicrob Agents Chemother. 2014;58:304\u20138.","journal-title":"Antimicrob Agents Chemother."},{"key":"576_CR65","doi-asserted-by":"publisher","first-page":"e01398-17","DOI":"10.1128\/AAC.01398-17","volume":"61","author":"JM Boonstra","year":"2017","unstructured":"Boonstra JM, van der Elst KC, Veringa A, Jongedijk EM, Br\u00fcggemann RJ, Koster RA, et al. Pharmacokinetic properties of micafungin in critically ill patients diagnosed with invasive candidiasis. Antimicrob Agents Chemother. 2017;61:e01398-17.","journal-title":"Antimicrob Agents Chemother."},{"key":"576_CR66","doi-asserted-by":"publisher","first-page":"e383","DOI":"10.1016\/S1473-3099(17)30316-X","volume":"17","author":"DS Perlin","year":"2017","unstructured":"Perlin DS, Rautemaa-Richardson R, Alastruey-Izquierdo A. The global problem of antifungal resistance: prevalence, mechanisms, and management. Lancet Infect Dis. 2017;17:e383\u201392.","journal-title":"Lancet Infect Dis."},{"key":"576_CR67","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1097\/FTD.0b013e31829591a7","volume":"35","author":"MJP Wanrooy van","year":"2013","unstructured":"van Wanrooy MJP, Santoe RN, van der Elst KCM, Wilmer CM, van Hateren K, Wessels AMA, et al. Simultaneous quantification of anidulafungin and caspofungin in plasma by an accurate and simple liquid chromatography tandem mass-spectrometric method. Ther Drug Monit. 2013;35:778\u201384.","journal-title":"Ther Drug Monit."},{"key":"576_CR68","doi-asserted-by":"publisher","first-page":"877","DOI":"10.4155\/bio-2017-0275","volume":"10","author":"JM Boonstra","year":"2018","unstructured":"Boonstra JM, Jongedijk EM, Koster RA, Touw DJ, Alffenaar JWC. Simple and robust LC-MS\/MS method for therapeutic drug monitoring of micafungin. Bioanalysis. 2018;10:877\u201386.","journal-title":"Bioanalysis."},{"key":"576_CR69","doi-asserted-by":"publisher","first-page":"i33","DOI":"10.1093\/jac\/dkx357","volume":"73","author":"F Pea","year":"2018","unstructured":"Pea F, Lewis RE. Overview of antifungal dosing in invasive candidiasis. J Antimicrob Chemother. 2018;73:i33\u201343.","journal-title":"J Antimicrob Chemother."},{"key":"576_CR70","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.1007\/s40262-015-0269-z","volume":"54","author":"K Vanstraelen","year":"2015","unstructured":"Vanstraelen K, Maertens J, Augustijns P, Lagrou K, de Loor H, Mols R, et al. Investigation of saliva as an alternative to plasma monitoring of voriconazole. Clin Pharmacokinet. 2015;54:1151\u201360.","journal-title":"Clin Pharmacokinet."},{"key":"576_CR71","doi-asserted-by":"publisher","first-page":"4999","DOI":"10.1128\/AAC.00707-13","volume":"57","author":"KCM Elst van der","year":"2013","unstructured":"van der Elst KCM, Span LFR, van Hateren K, Vermeulen KM, van der Werf TS, Greijdanus B, et al. Dried blood spot analysis suitable for therapeutic drug monitoring of voriconazole, fluconazole, and posaconazole. Antimicrob Agents Chemother. 2013;57:4999\u20135004.","journal-title":"Antimicrob Agents Chemother."},{"key":"576_CR72","volume-title":"Antimicrobial stewardship in Australian hospitals","year":"2010","unstructured":"Duguid M, Cruickshank M, editors. Antimicrobial stewardship in Australian hospitals. Sydney: Australian Commission on Safety and Quality in Healthcare; 2010."},{"key":"576_CR73","doi-asserted-by":"publisher","first-page":"2506","DOI":"10.1093\/jac\/dks256","volume":"67","author":"Y Nivoix","year":"2012","unstructured":"Nivoix Y, Launoy A, Lutun P, Moulin J-C, Phai Pang K-A, Fornecker L-M, et al. Adherence to recommendations for the use of antifungal agents in a tertiary care hospital. J Antimicrob Chemother. 2012;67:2506\u201313.","journal-title":"J Antimicrob Chemother."},{"key":"576_CR74","doi-asserted-by":"crossref","first-page":"1908","DOI":"10.1093\/jac\/dkv040","volume":"70","author":"C Micallef","year":"2015","unstructured":"Micallef C, Aliyu SH, Santos R, Brown NM, Rosembert D, Enoch DA. Introduction of an antifungal stewardship programme targeting high-cost antifungals at a tertiary hospital in Cambridge. England. J Antimicrob Chemother. 2015;70:1908\u201311.","journal-title":"England. J Antimicrob Chemother."},{"key":"576_CR75","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1086\/664909","volume":"33","author":"HC Standiford","year":"2012","unstructured":"Standiford HC, Chan S, Tripoli M, Weekes E, Forrest GN. Antimicrobial stewardship at a large tertiary care academic medical center: cost analysis before, during, and after a 7-year program. Infect Control Hosp Epidemiol. 2012;33:338\u201345.","journal-title":"Infect Control Hosp Epidemiol."}],"container-title":["Drugs & Aging"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40266-018-0576-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40266-018-0576-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40266-018-0576-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,28]],"date-time":"2022-08-28T05:36:09Z","timestamp":1661664969000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40266-018-0576-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,7,26]]},"references-count":75,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2018,9]]}},"alternative-id":["576"],"URL":"https:\/\/doi.org\/10.1007\/s40266-018-0576-9","relation":{},"ISSN":["1170-229X","1179-1969"],"issn-type":[{"value":"1170-229X","type":"print"},{"value":"1179-1969","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,7,26]]},"assertion":[{"value":"26 July 2018","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"BG.J. Dekkers, A. Veringa, D.J.E. Marriott, J.M. Boonstra, K.C.M. van der Elst, F.F. Doukas, A.J. McLachlan and J.W.C. Alffenaar received no external funding for this study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"B.G.J. Dekkers, A. Veringa, D.J.E. Marriott, J.M. Boonstra, K.C.M. van der Elst, F.F. Doukas, A.J. McLachlan and J.W.C. Alffenaar declare no conflicts of interest relevant to this paper.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}